Ransomware doesn't need to breach your control room it needs to get close enough that you can't trust it hasn't. Learn how attackers cross the IT-OT boundary, why segmentation keeps failing, and what penetration testing finds before they do.

Standard pen test scoping frameworks weren't built for pharma. Learn how to scope an engagement that covers validated systems under 21 CFR Part 11 and protects high-value formulation and clinical data from targeted threats.

Annual pen testing fits a budget cycle but it doesn't reflect how fast manufacturing environments actually change. Learn how to set a testing cadence based on rate of change, risk tolerance, and compliance requirements.

21 CFR Part 11 and cGMP don't mention penetration testing but the controls they require depend on it. Learn how to align your pharma pen test program with regulatory requirements and prepare for FDA data integrity inspections.

Nation-state actors treat pharma like critical infrastructure targeting formulation data, synthesis routes, and clinical IP with patience and precision. Learn why standard pen testing misses this threat and what adversary simulation reveals instead.